Introducing the science behind targeted treatments and immunotherapies for non-small cell lung cancer
10am - 12.30pmOnline, live event
Format: This is a live, virtual event. Each morning’s content is split over three sessions of 30-40 minutes each. Elaine will be online throughout both mornings to interact with learners and answer questions in the live Q&A sessions that follow each presentation. Recordings of the presentations will be available online for 30 days after the live event.
Description: Over the course of two mornings, Elaine will guide you through many of the most relevant topics relating to modern systemic treatments for non-small cell lung cancer (NSCLC).
The first morning’s focus is on the gene faults that drive many NSCLCs and on the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET and RET.
The second morning is about cancer’s relationship with the immune system and on the checkpoint inhibitor group of immunotherapies, which include PD-1, PD-L1 and CTLA-4 targeted antibody therapies.
As ever, Elaine's presentations are full of colourful and enlightening illustrations to help you make sense of scientific concepts. Her descriptions avoid unnecessary jargon and are pitched so that even those with a relatively limited understanding of cell biology are able to understand.
Audience: This content is ideal for research nurses, clinical nurse specialists, pharmacists and clinical trials coordinators. It may also be of interest to other healthcare professionals involved in the diagnosis and treatment of people with lung cancer.
Cost: £50 per morning; the content will be available for 30 days after the event